Junji Ichinose1, Aya Shinozaki-Ushiku2, Kazuhiro Nagayama3, Jun-Ichi Nitadori3, Masaki Anraku3, Masashi Fukayama2, Jun Nakajima3, Daiya Takai4. 1. Department of Thoracic Surgery, University of Tokyo Hospital, Tokyo, Japan. Electronic address: jichinose-tky@umin.ac.jp. 2. Department of Pathology, University of Tokyo Hospital, Tokyo, Japan. 3. Department of Thoracic Surgery, University of Tokyo Hospital, Tokyo, Japan. 4. Department of Clinical Laboratory, University of Tokyo Hospital, Tokyo, Japan.
Abstract
OBJECTIVES: This study aimed to develop an immunohistochemical (IHC) diagnostic algorithm for primary lung squamous cell carcinoma (LSCC) and pulmonary metastasis of head and neck SCC (HNSCC). MATERIALS AND METHODS: We selected three antibodies (CK19, MMP3, and PI3) from a web-based gene expression database and an IHC analysis available online. We developed an IHC diagnostic algorithm using tissue microarrays from 39 LSCCs and 48 HNSCCs as the training set. It was validated using whole tumor sections of 32 LSCCs and 23 HNSCCs. The algorithm was applied to 28 cases with a history of HNSCC and who underwent resection of pulmonary squamous cell tumors. RESULTS: The sensitivity, specificity, and accuracy of the algorithm were 90%, 62%, and 77%, respectively, in the training set and 96%, 44%, and 65%, respectively, in the validation set. Twenty-three of 28 SCCs were diagnosed as metastasis of HNSCC; the remaining five tumors were diagnosed as LSCC. Among the patients in the HNSCC group, 18 developed postoperative recurrence and 11 died of the disease, whereas only one patient in the LSCC group had recurrence. Compared with the LSCC group, the HNSCC group had poorer prognosis (P=0.07). IHC diagnosis coincided with the retrospective diagnosis in 22 (79%) of the 28 patients (sensitivity, 95%; specificity, 44%). CONCLUSION: The IHC diagnostic algorithm may be clinically useful for distinguishing between LSCC and pulmonary metastasis of HNSCC.
OBJECTIVES: This study aimed to develop an immunohistochemical (IHC) diagnostic algorithm for primary lung squamous cell carcinoma (LSCC) and pulmonary metastasis of head and neck SCC (HNSCC). MATERIALS AND METHODS: We selected three antibodies (CK19, MMP3, and PI3) from a web-based gene expression database and an IHC analysis available online. We developed an IHC diagnostic algorithm using tissue microarrays from 39 LSCCs and 48 HNSCCs as the training set. It was validated using whole tumor sections of 32 LSCCs and 23 HNSCCs. The algorithm was applied to 28 cases with a history of HNSCC and who underwent resection of pulmonary squamous cell tumors. RESULTS: The sensitivity, specificity, and accuracy of the algorithm were 90%, 62%, and 77%, respectively, in the training set and 96%, 44%, and 65%, respectively, in the validation set. Twenty-three of 28 SCCs were diagnosed as metastasis of HNSCC; the remaining five tumors were diagnosed as LSCC. Among the patients in the HNSCC group, 18 developed postoperative recurrence and 11 died of the disease, whereas only one patient in the LSCC group had recurrence. Compared with the LSCC group, the HNSCC group had poorer prognosis (P=0.07). IHC diagnosis coincided with the retrospective diagnosis in 22 (79%) of the 28 patients (sensitivity, 95%; specificity, 44%). CONCLUSION: The IHC diagnostic algorithm may be clinically useful for distinguishing between LSCC and pulmonary metastasis of HNSCC.
Authors: Hanibal Bohnenberger; Lars Kaderali; Philipp Ströbel; Diego Yepes; Uwe Plessmann; Neekesh V Dharia; Sha Yao; Carina Heydt; Sabine Merkelbach-Bruse; Alexander Emmert; Jonatan Hoffmann; Julius Bodemeyer; Kirsten Reuter-Jessen; Anna-Maria Lois; Leif Hendrik Dröge; Philipp Baumeister; Christoph Walz; Lorenz Biggemann; Roland Walter; Björn Häupl; Federico Comoglio; Kuan-Ting Pan; Sebastian Scheich; Christof Lenz; Stefan Küffer; Felix Bremmer; Julia Kitz; Maren Sitte; Tim Beißbarth; Marc Hinterthaner; Martin Sebastian; Joachim Lotz; Hans-Ulrich Schildhaus; Hendrik Wolff; Bernhard C Danner; Christian Brandts; Reinhard Büttner; Martin Canis; Kimberly Stegmaier; Hubert Serve; Henning Urlaub; Thomas Oellerich Journal: EMBO Mol Med Date: 2018-09 Impact factor: 12.137
Authors: A C H Willemsen; J H R J Degens; L W J Baijens; A-M C Dingemans; A Hoeben; F J P Hoebers; D K M De Ruysscher; A M W J Schols Journal: Front Nutr Date: 2020-11-26